TABLE 3

Adverse events during 36 months of treatment among patients enrolled in this study

Adverse eventNo. of patients (%)P
Experimental groupControl group
Skin discoloration5 (22.7)0 (0.0)0.014
Hepatic damage7 (31.8)3 (11.1)0.090
Renal damage2 (9.1)3 (11.1)1.000
Other1 (4.6)3 (11.1)0.617